{"id":36962,"date":"2026-07-15T20:45:00","date_gmt":"2026-07-15T18:45:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=4cd8c818d91099f5d73ac29187ffae6d"},"modified":"2026-07-15T20:45:00","modified_gmt":"2026-07-15T18:45:00","slug":"medincell-aligns-debt-maturity-with-its-expected-revenue-growth-trajectory-2","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=36962","title":{"rendered":"Medincell Aligns Debt Maturity With Its Expected Revenue Growth Trajectory"},"content":{"rendered":"

\nMore than 3 years extension of debt maturity to mid-2031, aligning it with expected revenue ramp-up primarily driven by marketed UZEDY\u00ae<\/sup> and Olanzapine LAI, which is currently under regulatory review in the U.S. and Europe<\/b><\/p><\/a><\/a>

\n\u20ac28 million in non-dilutive new bank loans secured from leading European commercial banks<\/b><\/p>

\nEarly repayment of half of the \u20ac40 million European Investment Bank (EIB) credit facility and the related capitalized interest, originally maturing in December 2027<\/b><\/p>

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:<\/p>

\nMedincell (Euronext Paris: MEDCL) today announced the completion of non-dilutive financing transactions designed to strengthen its financing profile and align debt maturities with the Company's expected revenue growth trajectory and future cash flows. These cash flows are expected to be primarily driven by milestones and royalties from UZEDY\u00ae<\/sup>, which is already marketed, and from Olanzapine LAI, currently under regulatory review in the U.S., with approval anticipated in Q4 2026. Both products are partnered with Teva.<\/p>

\nThe Company has secured \u20ac28 million in non-dilutive loans with leading European commercial banks, with no covenant or equity-linked instruments attached, strengthening its long-term cash position. In parallel, the Company will repay a \u20ac20 million tranche, together with related capitalized interests, of its existing \u20ac40 million European Investment Bank (EIB) credit facility entered into in 2022, by the end of July 2026.<\/p>

\nChristophe Douat, CEO of Medincell, said: <\/b>\u201cThis is a natural step in executing our \u2018Shift to Growth\u2019 strategy. As UZEDY sales continue to ramp up and we move closer to the potential commercial launch of Olanzapine LAI by our partner Teva, we are aligning our financial structure with our expected revenue growth. This strengthens our flexibility and supports the continued advancement of our pipeline of innovative products, aimed at generating recurring, high-margin revenues over time and creating sustainable long-term value.\u201d<\/i><\/p>

\nSt\u00e9phane Postic, CFO of Medincell, said: <\/b>\u201cThese non-dilutive debt financing transactions reflect the continued execution of a long-term financing strategy aligned with Medincell\u2019s growth trajectory. As of March 31, 2026, we held \u20ac84.8 million in cash and cash equivalents. We are further strengthening our financial resilience through a broader and more diversified base of financing partners and an extended debt maturity profile. In parallel, we continue to benefit from the support of the EIB, a longstanding strategic partner of the Company.\u201d<\/i><\/p>

\nDetail of Financing Transactions<\/b><\/p>

\nMedincell has secured \u20ac28 million loan from four European commercial banks. The facilities have a five-year maturity, with monthly or quarterly amortization of principal, and bear interest in line with current market conditions, with no covenant or equity-linked instruments attached. This financing strengthens the Company\u2019s long-term financial flexibility and overall cash profile.<\/p>

\nIn parallel, the Company will repay early the first tranche, corresponding to \u20ac20 million of principal, together with related capitalized interests, of its existing \u20ac40 million EIB credit facility, by the end of July 2026. Prior to the transaction, this tranche was fully repayable at maturity in December 2027. The remaining \u20ac20 million, initially repayable in half in January 2028 and July 2028, will shift to a partial amortizing profile. The Company will repay \u20ac200,000 monthly of principal together with a 5% cash interest, with a final one-off repayment of \u20ac17.5 million in July 2028. The transaction is expected to reduce the total financial costs associated with EIB financing by approximately \u20ac1 million over the remaining life of the facilities.<\/p>

\nAs a result, the repayment profile becomes more in line with the expected incoming cash flows, and the overall debt maturity is extended to July 2031.<\/p>

\nEIB debt profile before and after the transaction<\/b><\/p>\n\n\n\n\n

\n\u00a0<\/p><\/td>

\n

\nNominal amount:<\/b><\/p>

\n\u20ac40 million<\/b><\/p><\/td>

\nBefore transaction:\n\u20ac40 million outstanding<\/b><\/p><\/td>

\nAfter transaction:\n\u20ac20 million outstanding<\/b><\/p><\/td><\/tr>\n

\nEIB Tranches<\/b><\/p><\/td>

\nTranche A<\/b><\/p><\/td>

\n\u20ac20 million<\/p><\/td>

\nRepayable in full at maturity in December 2027 (with \u20ac4.3 million of capitalized interest)<\/p><\/td>

\nFully repaid (including \u20ac3.3 million of capitalized interest)<\/p><\/td><\/tr>\n

\nTranche B<\/b><\/p><\/td>

\n\u20ac10 million<\/p><\/td>

\nRepayable in full at maturity in January 2028 (with \u20ac1.6 million of capitalized interest)<\/p><\/td>

\n\u20ac200,000 monthly amortization of principal of newly combined Tranches B and C, together with a 5% cash interest, leading to a final \u20ac17.5 million bullet repayment in July 2028<\/p><\/td><\/tr>\n

\nTranche C<\/b><\/p><\/td>

\n\u20ac10 million<\/p><\/td>

\nRepayable in full at maturity in July 2028 (with \u20ac1.6 million of capitalized interest)<\/p><\/td><\/tr>\n<\/table>

\nDetailed terms of the initial EIB financing, including its remuneration and associated warrants, are described in the Company\u2019s press release dated November 23, 2022: <\/i>https:\/\/www.medincell.com\/wp-content\/uploads\/2024\/03\/20221123_PR-MdC-EIB-signature_EN.pdf<\/i><\/a><\/p>

\nThese terms have subsequently been supplemented by the press release announcing the waiver of the warrants put option dated March 26, 2026: <\/i>https:\/\/www.medincell.com\/wp-content\/uploads\/2026\/03\/PR_MDC_BEI_EN_260326.pdf<\/i><\/a><\/p>

\nAbout Medincell<\/b><\/p>

\nMedincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.<\/p>

\nThese treatments combine active pharmaceutical ingredients with our proprietary BEPO\u00ae<\/sup> \/ BEPO\u00ae<\/sup> Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable depot.<\/p>

\nRisperidone LAI was the first treatment based on BEPO\u00ae<\/sup> technology to receive FDA approval, initially for schizophrenia in April 2023, and subsequently for Bipolar I Disorder in October 2025. It is marketed in the United States by Teva under the brand name UZEDY\u00ae<\/sup>. Medincell\u2019s risperidone LAI was also approved for schizophrenia in Canada and South Korea in 2025.<\/p>

\nA New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment for schizophrenia in adults was submitted to the U.S. FDA in December 2025 by Medincell\u2019s partner, Teva. U.S. FDA accepted Teva\u2019s New NDA for Olanzapine LAI on February 20, 2026. A European Marketing Authorization Application (MAA) was also accepted by EMA in May 2026.<\/p>

\nMedincell\u2019s investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.<\/p>

\nHeadquartered in Montpellier, France, Medincell employs over 150 people representing more than 27 nationalities.<\/p>

\nmedincell.com<\/a><\/b><\/p>

\nUZEDY\u00ae<\/sup> is a trademark of Teva Pharmaceuticals. Medincell\u2019s BEPO\u00ae<\/sup> technology is licensed to Teva as SteadyTeq\u2122, a trademark of Teva Pharmaceuticals.<\/i><\/p>

\nThis press release contains forward-looking statements, including statements regarding Company\u2019s expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.<\/p>

\nThese statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as \"objective\", \"believe\", \"anticipate\", \u201cexpect\u201d, \"foresee\", \"aim\", \"intend\", \"may\", \"anticipate\", \"estimate\", \"plan\", \"project\", \"will\", \"may\", \"probably\", \u201cpotential\u201d, \"should\", \"could\" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorit\u00e9 des March\u00e9s Financiers (the \"AMF\") pursuant to its regulatory obligations, including the Company's universal registration document, filed with the AMF on July 29, 2025, under number D. 25-0580 (the \"Universal Registration Document\"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled \"Facteurs de Risques\" on page 30 of the Registration Document.<\/p>

\nAny forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.<\/p>

\nThis press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions.<\/p> Contacts<\/b>

\nDavid Heuz\u00e9<\/b>Head of Corporate and Financial Communications, and ESG\ndavid.heuze@Medincell.com<\/a> \/ +33 (0)6 83 25 21 86<\/p>

\nGrace Kim<\/b>Chief Strategy Officer, U.S. Finance\ngrace.kim@medincell.com<\/a> \/ +1 (646) 991-4023<\/p>

\nNicolas M\u00e9rigeau \/ Ga\u00eblle Fromaigeat<\/b>Media Relations\nMedincell@newcap.eu<\/a> \/ +33 (0)1 44 71 94 94<\/p>

\nLouis-Victor Delouvrier \/ Alban Dufumier<\/b>Investor Relations France\nMedincell@newcap.eu<\/a> \/ +33 (0)1 44 71 94 94<\/p>","protected":false},"excerpt":{"rendered":"

More than 3 years extension of debt maturity to mid-2031, aligning it with expected revenue ramp-up primarily driven by marketed UZEDY\u00ae and Olanzapine LAI, which is currently under regulatory review in the U.S. and Europe
\n\u20ac28 million in non-dilutive n…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-36962","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/36962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36962"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/36962\/revisions"}],"predecessor-version":[{"id":36964,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/36962\/revisions\/36964"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}